For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Acetylon Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 35

% Expired Patents = 8.6

CIPO Patents = 2

EPO Patents = 17

Forward Citations = 277

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

John Henry Van Duzer (18 out of 55 patents)

Ralph Mazitschek (16 out of 63 patents)

Steven N Quayle (11 out of 11 patents)

4. Simon Stewart Jones (10 out of 10 patents)

5. Min Yang (6 out of 6 patents)

6. Nan Yu (6 out of 6 patents)

7. David Lee Tamang (4 out of 4 patents)

8. James Bradner (4 out of 25 patents)

9. Guoxiang Huang (4 out of 11 patents)

10. Dejian Xie (4 out of 5 patents)

11. Walter Ogier (4 out of 4 patents)

12. Teru Hideshima (3 out of 14 patents)

13. Chengyin Min (3 out of 3 patents)

14. Kenneth Carl Anderson (3 out of 40 patents)

15. Yun Cao (2 out of 9 patents)

Core Competencies:

Histone Deacetylase Inhibitors

CD38 Inhibitors

Aurora Kinase Inhibitors

BCL-2 Inhibitors

Immunomodulatory Drugs

PD-L1 Inhibitors

Selective HDAC Inhibitors

Protein Deacetylase Inhibitors

Chronic Lymphocytic Leukemia

Biomarkers

Phenyl Hydroxamic Acids

Pyrimidine Hydroxy Amide Compounds

35 patents: Sort by Forward Citations

1. 12053468 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2024-08-06),

2. 11998546 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof (2024-06-04),

3. 11872227 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof (2024-01-16),

4. 11813261 - HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia (2023-11-14),

5. 11666568 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof (2023-06-06),

6. 11617750 - Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof (2023-04-04),

7. 11497746 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof (2022-11-15),

8. 11357776 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof (2022-06-14),

9. 11337975 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2022-05-24),

10. 11324744 - Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies (2022-05-10),

11. 11311540 - Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs (2022-04-26),

12. 11298354 - Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors (2022-04-12),

13. 10927072 - Phenyl and pyridinyl hydroxamic acids (2021-02-23),

14. 10722512 - Combinations of histone deacetylase inhibitors and either HER2 inhibitors or PI3K inhibitors (2020-07-28),

15. 10648038 - Biomarkers to identify patients that will respond to treatment and treating such patients (2020-05-12),

Company Overview

Acetylon Pharmaceuticals, Inc. is a biotechnology company based in Boston, MA, specializing in the development of innovative therapies for cancer and other serious diseases. The company focuses on harnessing the power of epigenetics to create novel treatments that target specific molecular pathways involved in disease progression. By leveraging advanced research in drug discovery and development, Acetylon aims to improve patient outcomes and address unmet medical needs through its cutting-edge therapeutic approaches.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

35 Patents

#69 in Boston, MA

#585 in Massachusetts

#9,766 in US

#19,196 in the World

Boston, MA, United States of America

Acetylon Pharmaceuticals, Inc.

Forward Citations = 277

29 inventors:

John Henry Van Duzer (18 out of 55 patents)

Ralph Mazitschek (16 out of 63 patents)

Steven N Quayle (11 out of 11 patents)

4. Simon Stewart Jones (10 out of 10 patents)

5. Min Yang (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Acetylon Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/acetylon-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…